The third quarter US sales for Regeneron’s Eylea were listed as $1.02 billion. This is the first time the drug has generated over $1 billion in quarterly US sales. Q2 sales were $992 million. In August, Eylea received an FDA nod in wet age-related macular degeneration as a 12-week dosing formulation, and the agency is scheduled to decide on the drug’s use in diabetic retinopathy by May 13, 2019.
Click here to view the entire article.